Renal effects of long-term darbepoetin alpha treatment in hypertensive TGR(mRen2)27 rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 2, 2012, Pages 232-238

  Frenay, Anne Roos S ^a   Ruifrok, Willem Peter T ^a   Bulthuis, Marian ^a   Huitema, Sippie ^a   De Boer, Rudolf A ^a   Van Goor, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACEi; darbepoetin alpha; hypertension; kidney; Ren2; renin angiotensin system

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; COLLAGEN TYPE 3; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; KIDNEY INJURY MOLECULE 1; LISINOPRIL; MESSENGER RNA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; HEMATOCRIT; HISTOPATHOLOGY; HYPERTENSION; KIDNEY; LONG TERM CARE; MALE; NONHUMAN; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84861883272     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311432186     Document Type: Article

References (24)

1. Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996 ; 50: 1321-1326 (Pubitemid 26342825)
2. de Boer RA, Pokharel S, Flesch M, et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med. 2004 ; 82: 678-687 (Pubitemid 39468492)
3. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progresion of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008 ; 74: 867-872
4. Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009 ; 30: 253-260
5. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions-cardiovascular protection. Semin Hematol. 2007 ; 44: 212-217 (Pubitemid 47031230)
6. Sharples EJ, Yaqoob MM. Erythropoietin and acute renal failure. Semin Nephrol. 2006 ; 26: 325-331 (Pubitemid 44722453)
7. Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephol. 2005 ; 1: 87-97
8. Teng R, Calvert JW, Sibmooh N, et al. Acute erythropoietin cardioprotection is mediated by endotelial response. Basic Res Cardiol. 2011 ; 106: 343-354
9. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006 ; 69: 1806-1813 (Pubitemid 43739209)
10. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertension. 2008 ; 21: 1288-1291
11. Kuipers I, van der Harst P, Kuipers F, et al. Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin- aldosterone system. Lab Invest. 2010 ; 90: 630-636
12. Hamming I, Navis G, Kocks MJ, van Goor H. Adverse renal effects of ACE inhibition during dietary sodium restriction in proteinuric and healthy rats. J Pathol. 2006 ; 209: 129-139
13. de Borst MH, Navis G, de Boer RA, et al. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab Invest. 2003 ; 83: 1761-1770 (Pubitemid 38018539)
14. de Borst MH, van Timmeren MM, Vaidya VS, et al. Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase. Am J Physiol Renal Physiol. 2007 ; 292: F313-320
15. Ruifrok WT, Qian C, Silljé HHW, et al. Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. J Mol Med. 2011 ; 89: 377-387
16. Forman CJ, Johnson DW, Nicol DL. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int. 2007 ; 99: 162-165 (Pubitemid 44915640)
17. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and disfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004 ; 15: 2115-2124 (Pubitemid 39031350)
18. Yang B, Hosgood SA, Bagul A, Waller HL, Nicholson ML. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys. Eur J Pharmacol. 2011 ; 660: 420-430
19. Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant. 2006 ; 21: 330-336 (Pubitemid 43159985)
20. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004 ; 19: 348-355 (Pubitemid 38195983)
21. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004 ; 110: 1006-1012 (Pubitemid 39128626)
22. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens. 2009 ; 18: 15-20
23. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004 ; 44: 473-479 (Pubitemid 39305089)
24. Westenbrink BD, Oeseburg H, Kleijn L, et al. Erythropoietin stimulates normal endogenitor progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther. 2008 ; 22: 265-274